EXAMINE THIS REPORT ON AGO TUMOR

Hormonal therapy stays the remedy of first choice for metastatic patients with endocrine-responsive breast cancer (LoE 1a A, AGO ++). The sequential use of the accessible medicines relies on the person pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at enough time of diagnosis of relapse is suggested whenever doable, so that you can